CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges
Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigen...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12 February 2020
|
| In: |
Briefings in functional genomics
Year: 2020, Volume: 19, Issue: 3, Pages: 209-214 |
| ISSN: | 2041-2657 |
| DOI: | 10.1093/bfgp/elaa001 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/bfgp/elaa001
|
| Author Notes: | Xing Chen, Shaoyi Fan, Chengcai Wen and Xianfa Du |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1797404792 | ||
| 003 | DE-627 | ||
| 005 | 20220820160040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220402s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/bfgp/elaa001 |2 doi | |
| 035 | |a (DE-627)1797404792 | ||
| 035 | |a (DE-599)KXP1797404792 | ||
| 035 | |a (OCoLC)1341458048 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cheng, Xing |d 1991- |e VerfasserIn |0 (DE-588)1222055252 |0 (DE-627)1740888790 |4 aut | |
| 245 | 1 | 0 | |a CRISPR/Cas9 for cancer treatment |b technology, clinical applications and challenges |c Xing Chen, Shaoyi Fan, Chengcai Wen and Xianfa Du |
| 246 | 3 | 0 | |a DOI 10.1093/bfgp/elaa018 |
| 264 | 1 | |c 12 February 2020 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Verlagskorrektur erschienen am 23. September 2020 mit dem DOI 10.1093/bfgp/elaa018 wegen falsch buchstabierten Namens für Herrn Xing Cheng | ||
| 500 | |a Gesehen am 02.04.2022 | ||
| 520 | |a Clustered regularly interspaced short palindromic repeats (CRISPR) is described as RNA mediated adaptive immune system defense, which is naturally found in bacteria and archaea. CRISPR-Cas9 has shown great promise for cancer treatment in cancer immunotherapy, manipulation of cancer genome and epigenome and elimination or inactivation of carcinogenic viral infections. However, many challenges remain to be addressed to increase its efficacy, including off-target effects, editing efficiency, fitness of edited cells, immune response and delivery methods. Here, we explain CRISPR-Cas classification and its general function mechanism for gene editing. Then, we summarize these preclinical CRISPR-Cas9-based therapeutic strategies against cancer. Moreover, the challenges and improvements of CRISPR-Cas9 clinical applications will be discussed. | ||
| 700 | 1 | |a Fan, Shaoyi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wen, Chengcai |e VerfasserIn |4 aut | |
| 700 | 1 | |a Du, Xianfa |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Briefings in functional genomics |d Oxford : Oxford Univ. Press, 2010 |g 19(2020), 3, Seite 209-214 |h Online-Ressource |w (DE-627)620141514 |w (DE-600)2540929-3 |w (DE-576)33496640X |x 2041-2657 |7 nnas |a CRISPR/Cas9 for cancer treatment technology, clinical applications and challenges |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:3 |g pages:209-214 |g extent:6 |a CRISPR/Cas9 for cancer treatment technology, clinical applications and challenges |
| 856 | 4 | 0 | |u https://doi.org/10.1093/bfgp/elaa001 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220402 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1222055252 |a Cheng, Xing |m 1222055252:Cheng, Xing |d 50000 |e 50000PC1222055252 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1797404792 |e 4111580920 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"6 S."}],"relHost":[{"title":[{"title_sort":"Briefings in functional genomics","title":"Briefings in functional genomics"}],"part":{"year":"2020","pages":"209-214","issue":"3","text":"19(2020), 3, Seite 209-214","volume":"19","extent":"6"},"pubHistory":["9.2010 -"],"recId":"620141514","language":["eng"],"note":["Gesehen am 20.01.2025"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"CRISPR/Cas9 for cancer treatment technology, clinical applications and challengesBriefings in functional genomics","id":{"issn":["2041-2657"],"eki":["620141514"],"zdb":["2540929-3"]},"origin":[{"dateIssuedDisp":"2010-","publisher":"Oxford Univ. Press","dateIssuedKey":"2010","publisherPlace":"Oxford"}],"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Xing Chen, Shaoyi Fan, Chengcai Wen and Xianfa Du"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"12 February 2020"}],"id":{"doi":["10.1093/bfgp/elaa001"],"eki":["1797404792"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Verlagskorrektur erschienen am 23. September 2020 mit dem DOI 10.1093/bfgp/elaa018 wegen falsch buchstabierten Namens für Herrn Xing Cheng","Gesehen am 02.04.2022"],"language":["eng"],"recId":"1797404792","person":[{"role":"aut","display":"Cheng, Xing","roleDisplay":"VerfasserIn","given":"Xing","family":"Cheng"},{"given":"Shaoyi","family":"Fan","role":"aut","roleDisplay":"VerfasserIn","display":"Fan, Shaoyi"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Wen, Chengcai","given":"Chengcai","family":"Wen"},{"given":"Xianfa","family":"Du","role":"aut","roleDisplay":"VerfasserIn","display":"Du, Xianfa"}],"title":[{"title":"CRISPR/Cas9 for cancer treatment","subtitle":"technology, clinical applications and challenges","title_sort":"CRISPR/Cas9 for cancer treatment"}]} | ||
| SRT | |a CHENGXINGFCRISPRCAS91220 | ||